共 18 条
[1]
Receptor interacting protein kinase 3 is a critical early mediator of acetaminophen‐induced hepatocyte necrosis in mice[J] Anup Ramachandran;Mitchell R. McGill;Yuchao Xie;Hong‐Min Ni;Wen‐Xing Ding;Hartmut Jaeschke Hepatology 2013,
[2]
High lipophilicity and high daily dose of oral medications are associated with significant risk for drug‐induced liver injury[J] Minjun Chen;Jürgen Borlak;Weida Tong Hepatology 2013,
[3]
Role of Kupffer cells and toll-like receptor 4 in acetaminophen-induced acute liver failure[J] James E. Fisher;Travis J. McKenzie;Joseph B. Lillegard;Yue Yu;Justin E. Juskewitch;Geir I. Nedredal;Gregory J. Brunn;Eunhee S. Yi;Thomas C. Smyrk;Scott L. Nyberg;Harmeet Malhi Journal of Surgical Research 2013,
[4]
CHOP is a critical regulator of acetaminophen-induced hepatotoxicity<!-- Doctopic: LFG -->[J] Dotan Uzi;Liran Barda;Viviana Scaiewicz;Maya Mills;Tobias Mueller;Agueda Gonzalez-Rodriguez;Angela M. Valverde;Takao Iwawaki;Yaacov Nahmias;Ramnik Xavier;Ray T. Chung;Boaz Tirosh;Oren Shibolet Journal of Hepatology 2013,
[5]
Human leukocyte antigen (HLA)‐B*57:01‐restricted activation of drug‐specific T cells provides the immunological basis for flucloxacillin‐induced liver injury[J] Manal M. Monshi;Lee Faulkner;Andrew Gibson;Rosalind E. Jenkins;John Farrell;Caroline J. Earnshaw;Ana Alfirevic;Karin Cederbrant;Ann K. Daly;Neil French;Munir Pirmohamed;B. Kevin Park;Dean J. Naisbitt Hepatology 2013,
[6]
Genetic risk factors for drug-induced liver injury in rheumatoid arthritis patients using low-dose methotrexate[J] Cristina Lucía Dávila-Fajardo;Jesse J Swen;José Cabeza Barrera;Henk-Jan Guchelaar Pharmacogenomics 2013,
[7]
Acetaminophen-induced liver injury in rats and mice: Comparison of protein adducts; mitochondrial dysfunction; and oxidative stress in the mechanism of toxicity[J] Mitchell R. McGill;C. David Williams;Yuchao Xie;Anup Ramachandran;Hartmut Jaeschke Toxicology and Applied Pharmacology 2012,
[8]
A single nucleotide polymorphism tags variation in the arylamine N-acetyltransferase 2 phenotype in populations of European background[J] Montserrat García-Closas;David W. Hein;Debra Silverman;Núria Malats;Meredith Yeager;Kevin Jacobs;Mark A. Doll;Jonine D. Figueroa;Dalsu Baris;Molly Schwenn;Manolis Kogevinas;Alison Johnson;Nilanjan Chatterjee;Lee E. Moore;Timothy Moeller;Francisco X. Real;Stephen Chanock;Nathaniel Rothman Pharmacogenetics and Genomics 2011,
[9]
Pharmacogenetics of drug‐induced liver injury[J] Stefan Russmann;Alexander Jetter;Gerd A. Kullak‐Ublick Hepatology 2010,
[10]
Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events[J] Craig Lammert;Einar Bjornsson;Anna Niklasson;Naga Chalasani Hepatology 2010,